Drugs / PU-AD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03371420 | Apr 2016 → Jun 2019 | Alzheimer disease, plasma cell myeloma | Samus Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PU-AD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03371420 ↗ |
| Route | Intravenous | “A single dose of 124I-PU-AD will be administered by intravenous (IV) injection to subjects.” NCT03371420 ↗ |